{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:06:40Z","timestamp":1789693600898,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:04:59Z","timestamp":1787083499000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?"],"prefix":"10.1016","volume":"212","author":[{"given":"Chiara","family":"Ainio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapaola Antonia","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina N.","family":"Rosanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela I.","family":"Causa-Andrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceylan","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Stolpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi A.","family":"De Vitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanika","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Langstraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela E.","family":"McGree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Multinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Ostby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Schivardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni D.","family":"Aletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.08.011_bb0005","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2023) <Katrina\/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released February 2025. Underlying mortality data provided by NCHS (www.cdc.gov\/nchs)."},{"key":"10.1016\/j.ygyno.2026.08.011_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2023.10.018","article-title":"Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: a systematic review and meta-analysis","volume":"179","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2026.08.011_bb0015","doi-asserted-by":"crossref","first-page":"TPS5602","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5602","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 \/ AGO-OVAR OP7)","volume":"35","author":"Mahner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.011_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116116","article-title":"Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III\u2013IV epithelial ovarian cancer: a systematic review and meta-analysis","volume":"232","author":"Secchi","year":"2026","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.011_bb0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.08.011_bb0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/ijgc-2021-003320","article-title":"CHRONO: randomized trial of the CHROnology of surgery after neoadjuvant chemotherapy for ovarian cancer","volume":"32","author":"Classe","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2026.08.011_bb0035","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1136\/ijgc-2022-004249","article-title":"Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma","volume":"33","author":"Perrone","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.011_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2025.06.024","article-title":"Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer","volume":"199","author":"Ainio","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.011_bb0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.05.009","article-title":"Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"187","author":"Filippova","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.08.011_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2023.01.017","article-title":"Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy","volume":"172","author":"Jorgensen","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.011_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/ijgc-2018-000012","article-title":"The international mission study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy","volume":"29","author":"Fagotti","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2026.08.011_bb0060","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ijgc-2019-000971","article-title":"Minimally invasive interval cytoreductive surgery: it\u2019s time for a randomized trial","volume":"29","author":"Melamed","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.08.011_bb0065","series-title":"Obstetrics and Gynecology","first-page":"861","article-title":"Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy","volume":"Vol 129","author":"Melamed","year":"2017"},{"issue":"11","key":"10.1016\/j.ygyno.2026.08.011_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.46325","article-title":"Laparoscopic cytoreduction after neoadjuvant chemotherapy in high-grade epithelial ovarian cancer: a LANCE randomized clinical trial","volume":"7","author":"Rauh-Hain","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.011_bb0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","article-title":"A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer","volume":"134","author":"Suidan","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.011_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2017.02.020","article-title":"A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer","volume":"145","author":"Suidan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.08.011_bb0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2019.04.011","article-title":"Models to predict outcomes after primary debulking surgery: independent validation of models to predict suboptimal cytoreduction and gross residual disease","volume":"154","author":"Kumar","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.011_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.acra.2019.09.019","article-title":"The value of contrast-enhanced CT in the detection of residual disease after neo-adjuvant chemotherapy in ovarian cancer","volume":"27","author":"An","year":"2020","journal-title":"Acad. Radiol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.08.011_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2018.12.012","article-title":"CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy","volume":"152","author":"Bregar","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.011_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.08.011_bb0105","doi-asserted-by":"crossref","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"7624","key":"10.1016\/j.ygyno.2026.08.011_bb0110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von","year":"2007","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ygyno.2026.08.011_bb0115","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1007\/s00330-024-11300-7","article-title":"Ovarian cancer staging and follow-up: updated guidelines from the European Society of Urogenital Radiology female pelvic imaging working group","volume":"35","author":"Rizzo","year":"2025","journal-title":"Eur. Radiol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.011_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020500","article-title":"Concordance of radiological, laparoscopic and laparotomic scoring to predict complete cytoreduction in women with advanced ovarian cancer","volume":"15","author":"Di Donna","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2026.08.011_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-025-08173-6","article-title":"Impact of diagnostic laparoscopy on resectability and treatment strategy in FIGO III\u2013IV ovarian cancer","author":"Endres","year":"2025","journal-title":"Arch. Gynecol. Obstet."},{"issue":"8","key":"10.1016\/j.ygyno.2026.08.011_bb0130","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.08.011_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin\u2013paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:42:30Z","timestamp":1789692150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0090825826021037"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}